» Articles » PMID: 39860378

Risk-Stratified Venous Thromboembolism Chemoprophylaxis After Total Joint Arthroplasty: Evaluation of an Institutional Approach

Overview
Journal J Clin Med
Date 2025 Jan 25
PMID 39860378
Authors
Affiliations
Soon will be listed here.
Abstract

: The optimal venous thromboembolism (VTE) chemoprophylaxis approach after hip or knee total joint arthroplasty (TJA) remains controversial. This study aimed to characterize antithrombotic-related complications associated with various chemoprophylaxis regimens after TJA and to assess our current institutional risk-stratified prescribing tool. : This retrospective case-control study and regression analysis included elective unilateral TJA patients at a single institution between 1 July 2015 and 31 December 2021. The primary outcome was a composite of antithrombotic-related complications within 30 days of surgery, including thrombotic and hemorrhagic/wound-related adverse events. The duration of anticoagulant chemoprophylaxis prescribed prior to aspirin monotherapy (0-28 days) was compared between patients who did vs. did not experience a complication, with stratification by institutionally defined VTE risk categories (Routine, Moderate, or High Risk). The complication rate was then assessed as a function of anticoagulant duration within each risk subgroup. : The study included 5420 patients, with 279 (5.2%) experiencing ≥1 complication. Routine VTE risk patients experienced few complications, with no significant difference between aspirin monotherapy and various initial anticoagulant durations ( = 0.6118). Moderate and High VTE Risk patients saw significantly lower complication rates with initial anticoagulant prophylaxis of increasing durations ( = 0.0090 and = 0.0050), with a significant overall effect of VTE Risk strata observed ( = 0.0006). : When both bleeding and thrombotic events are considered, anticoagulant-to-aspirin regimens were associated with lower complication rates than aspirin monotherapy in higher risk patients, while routine patients saw no significant benefit over aspirin. Our risk-stratified prescribing approach should be prospectively evaluated.

References
1.
Barrett M, Whitehouse M, Blom A, Kunutsor S . Host-related factors for venous thromboembolism following total joint replacement: A meta-analysis of 89 observational studies involving over 14 million hip and knee replacements. J Orthop Sci. 2019; 25(2):267-275. DOI: 10.1016/j.jos.2019.04.003. View

2.
Colleoni J, Ribeiro F, Mos P, Reis J, Oliveira H, Miura B . Venous thromboembolism prophylaxis after total knee arthroplasty (TKA): aspirin rivaroxaban. Rev Bras Ortop. 2018; 53(1):22-27. PMC: 5771791. DOI: 10.1016/j.rboe.2017.11.007. View

3.
Hyland S, Kramer B, Fada R, Lucki M . Clinical Pharmacist Service Associated With Improved Outcomes and Cost Savings in Total Joint Arthroplasty. J Arthroplasty. 2020; 35(9):2307-2317.e1. DOI: 10.1016/j.arth.2020.04.022. View

4.
Falck-Ytter Y, Francis C, Johanson N, Curley C, Dahl O, Schulman S . Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2 Suppl):e278S-e325S. PMC: 3278063. DOI: 10.1378/chest.11-2404. View

5.
Ren Y, Cao S, Li Z, Luo T, Feng B, Weng X . Comparable efficacy of 100 mg aspirin twice daily and rivaroxaban for venous thromboembolism prophylaxis following primary total hip arthroplasty: a randomized controlled trial. Chin Med J (Engl). 2021; 134(2):164-172. PMC: 7817327. DOI: 10.1097/CM9.0000000000001305. View